Experimental cell therapy targets kidney disease

NCT ID NCT07389499

Not yet recruiting Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will enroll 30 adults to first assess safety and find the right dose, then expand to evaluate effectiveness more closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT719 universal cell injection (CD19-targeted iNKT cells)
What this could lead to: If it works, this could point toward a new treatment option for certain immune-mediated kidney diseases, potentially reducing the need for long-term immunosuppression.
What could go wrong: This is a very early (Phase 1) trial with only 30 participants, so safety and effectiveness are not yet proven. Cell therapies can have serious side effects, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED GLOMERULONEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis IgA glomerulonephritis membranous glomerulonephritis non-amyloid monoclonal immunoglobulin deposition disease pauci-immune glomerulonephritis with ANCA proliferative glomerulonephritis steroid-resistant nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS (AAV)/ANCA-ASSOCIATED GLOMERULONEPHRITIS (AAGN) IGA NEPHROPATHY (IGAN) MEMBRANOUS NEPHROPATHY PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITS REFRACTORY PODOCYTOPATHY

Contacts and locations

Locations

Zhongshan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.